MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 10, 2004; DOI: 10.1124/mol.104.006049


0026-895X/05/6702-541-544$20.00
Mol Pharmacol 67:541-544, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.006049v1
67/2/541    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welling, A.
Right arrow Articles by Wegener, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welling, A.
Right arrow Articles by Wegener, J. W.
ORIGINAL ARTICLE

Inhibition of L-Type Cav1.2 Ca2+ Channels by 2,(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-Dimethyl-aminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) Maleimide (Gö6983)

A. Welling, F. Hofmann, and J. W. Wegener

Institut für Pharmakologie und Toxikologie, Technische Universität München, München, Germany

Abstract

Phosphatidylinositol 3-kinase (PI3-K) is involved in physiological processes of cellular proliferation and inflammation and, as postulated recently, in the regulation of L-type Ca2+ channels. The latter conclusion arose in part from the inhibitory action of the compound 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), which has been established as a selective PI3-K inhibitor (IC50 = 1.4 µM). Herein we show, however, that LY294002 and an inhibitor of protein kinase C (PKC), 2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide (Gö6983), act as direct Ca2+-channel inhibitors, with IC50 values of approximately 20 and 10 µM, respectively. Because both drugs are commonly used at concentrations of approximately 10 µM or higher, the interpretation of such experiments is questionable with respect to a regulatory action of PI3-K or PKC on L-type Ca2+ channels.


Received August 11, 2004; accepted November 9, 2004

Address correspondence to: Dr. J. W. Wegener, Institut für Pharmakologie und Toxikologie, Technische Universität München, Biedersteiner Str. 29, 80802 München, Germany. E-mail: wegener{at}ipt.med.tu-muenchen.de




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Azam, K. Yoshioka, S. Ohkura, N. Takuwa, N. Sugimoto, K. Sato, and Y. Takuwa
Ca2+-Independent, Inhibitory Effects of Cyclic Adenosine 5'-Monophosphate on Ca2+ Regulation of Phosphoinositide 3-Kinase C2{alpha}, Rho, and Myosin Phosphatase in Vascular Smooth Muscle
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 907 - 916.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Physiol.Home page
D. M. Browe and C. M. Baumgarten
EGFR Kinase Regulates Volume-sensitive Chloride Current Elicited by Integrin Stretch via PI-3K and NADPH Oxidase in Ventricular Myocytes
J. Gen. Physiol., February 27, 2006; 127(3): 237 - 251.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics